A brand-new lab facility is soon to be opening within the heart of Newcastle’s £350m urban development scheme - Newcastle Helix.
The Biosphere will provide a home for ambitious companies within life sciences and innovation, research and development. This is all part of the city’s wider commitment to support economic development and growth within the life sciences sector.
AMSBIO has added an important new product to its immunotherapy range - a PD-L2 / TCR activator - CHO Recombinant Cell Line.
PD-L2 is one of the key players in immune checkpoint therapy, which is the focus of the 2018 Nobel Prize for Physiology & Medicine . This work pioneered by Professor James P Allison from the USA and Professor Tasuku Honjo from Japan, has led to treatments for cancers, such as melanoma, lung cancer and others based upon immune checkpoint therapy.
GiroNEX Ltd – a new Cambridgeshire-based technology spin-out – has announced today first details of a novel precision powder dispensing technology that could significantly increase the pharmaceutical industry’s ability to offer patient-specific dosing for more effective treatment of specific conditions.
Genomics England names Congenica as Clinical Decision Support Service partner for the delivery of the NHS Genomic Medicine Service
17 October 2018
Cambridge, UK, 15 October 2018 – F-star, a clinical-stage biopharmaceutical company pioneering the development of novel bispecific antibodies that target the immune system to fight cancer, today announced the appointment of Dr Eliot Forster as Chief Executive Officer. Dr Forster succeeds former CEO Dr John Haurum.
Royalty bearing license agreement to commercialise a product incorporating the Affimer technology
Cambridge, UK, Oct 10 2018: Owlstone Medical (or the “Company”), a global diagnostics company developing a breathalyzer for applications in early disease detection and precision medicine, today announces the appointment of Dr. Richard A Yost to its Scientific Advisory Board.
Life science businesses can learn all about new plans to improve personalised healthcare, at an Interreg North-West Europe event, hosted by the University of Leicester and supported by Medilink Midlands.
Acquired donor center and laboratory enables BioIVT to ship high quality blood products and blood-derived immune cells efficiently to researchers throughout Europe
Westbury, NY – Oct. 8, 2018 – BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Clinical Trials Laboratory Services (CTLS), a donor center and laboratory based in London, UK. CTLS provides dedicated high-quality serum, plasma and blood collection services. It also offers full-service cell processing capabilities on site.
Glasgow, UK based - ScreenIn3D, a partner of AMSBIO, reports on the accolades it has received following the recent launch of its novel microfluidic cancer screening service.
Combining the latest advances in microfluidics and 3D culture - the service uses an optimised screening platform targeted at improving anticancer drug treatment and accelerating development of new personalised medicine solutions.